β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion

Cell Reports

Volumn 22, Issue 7, 2018, Pages 1774-1786

  Böni Schnetzler, Marianne ^a,b   Häuselmann, Stéphanie P ^a,b   Dalmas, Elise ^a,b   Meier, Daniel T ^a,b   Thienel, Constanze ^a,b   Traub, Shuyang ^a,b   Schulze, Friederike ^a,b   Steiger, Laura ^a,b   Dror, Erez ^a,b   Martin, Praxedis ^c   Herrera, Pedro L ^d   Gabay, Cem ^c   Donath, Marc Y ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Centre médical universitaire   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ATP sensitive K+ channel subunit Kir6.2; diabetes; E2F1 transcription factor; glucose stimulated insulin secretion; IL 1 receptor antagonist; interleukin 1 ; islet cells; cell proliferation

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; TRANSCRIPTION FACTOR E2F1; BIOLOGICAL MARKER; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GLUCOSE TOLERANCE; INSULIN RELEASE; KNOCKOUT MOUSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; C57BL MOUSE; DRUG EFFECT; GLUCOSE INTOLERANCE; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; BIOMARKERS; CELL PROLIFERATION; E2F1 TRANSCRIPTION FACTOR; GENE DELETION; GLUCOSE; GLUCOSE INTOLERANCE; INSULIN SECRETION; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; MYELOID CELLS; OBESITY; ORGAN SPECIFICITY;

EID: 85042043462     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.01.063     Document Type: Article

References (52)

1. Alejandro, E.U., Lim, G.E., Mehran, A.E., Hu, X., Taghizadeh, F., Pelipeychenko, D., Baccarini, M., Johnson, J.D., Pancreatic β-cell Raf-1 is required for glucose tolerance, insulin secretion, and insulin 2 transcription. FASEB J. 25 (2011), 3884–3895.
2. Annicotte, J.S., Blanchet, E., Chavey, C., Iankova, I., Costes, S., Assou, S., Teyssier, J., Dalle, S., Sardet, C., Fajas, L., The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat. Cell Biol. 11 (2009), 1017–1023.
3. Arend, W.P., Malyak, M., Guthridge, C.J., Gabay, C., Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16 (1998), 27–55.
4. Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J.H., Dinarello, C.A., Svenson, M., Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232 (1986), 1545–1547.
5. Benner, C., van der Meulen, T., Cacéres, E., Tigyi, K., Donaldson, C.J., Huising, M.O., The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics, 15, 2014, 620.
6. Böni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J.A., Kerr-Conte, J., Pattou, F., Halban, P.A., Weir, G.C., Donath, M.Y., Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93 (2008), 4065–4074.
7. Böni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D.T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J.A., Schuit, F.C., Donath, M.Y., Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150 (2009), 5218–5229.
8. 18 F]-IL1RA and PET imaging in rats. Br. J. Pharmacol. 162 (2011), 659–672.
9. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Förster, I., Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999), 265–277.
10. Corbett, J.A., McDaniel, M.L., Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J. Exp. Med. 181 (1995), 559–568.
11. Corbett, J.A., Sweetland, M.A., Wang, J.L., Lancaster, J.R. Jr., McDaniel, M.L., Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. USA 90 (1993), 1731–1735.
12. Cuylen, S., Blaukopf, C., Politi, A.Z., Müller-Reichert, T., Neumann, B., Poser, I., Ellenberg, J., Hyman, A.A., Gerlich, D.W., Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature 535 (2016), 308–312.
13. Dalmas, E., Lehmann, F.M., Dror, E., Wueest, S., Thienel, C., Borsigova, M., Stawiski, M., Traunecker, E., Lucchini, F.C., Dapito, D.H., et al. Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production. Immunity 47 (2017), 928–942.e27.
14. Dinarello, C.A., Overview of the interleukin-1 family of ligands and receptors. Semin. Immunol. 25 (2013), 389–393.
15. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 (2011), 98–107.
16. Donath, M.Y., Dalmas, É., Sauter, N.S., Böni-Schnetzler, M., Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17 (2013), 860–872.
17. Dror, E., Dalmas, E., Meier, D.T., Wueest, S., Thévenet, J., Thienel, C., Timper, K., Nordmann, T.M., Traub, S., Schulze, F., et al. Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat. Immunol. 18 (2017), 283–292.
18. Drucker, D.J., Never waste a good crisis: confronting reproducibility in translational research. Cell Metab. 24 (2016), 348–360.
19. Eguchi, K., Manabe, I., Oishi-Tanaka, Y., Ohsugi, M., Kono, N., Ogata, F., Yagi, N., Ohto, U., Kimoto, M., Miyake, K., et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 15 (2012), 518–533.
20. Ehses, J.A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J.A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M.K., Biollaz, G., et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56 (2007), 2356–2370.
21. Fajas, L., Annicotte, J.S., Miard, S., Sarruf, D., Watanabe, M., Auwerx, J., Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/-)mice. J. Clin. Invest. 113 (2004), 1288–1295.
22. Girard, C.A., Wunderlich, F.T., Shimomura, K., Collins, S., Kaizik, S., Proks, P., Abdulkader, F., Clark, A., Ball, V., Zubcevic, L., et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J. Clin. Invest. 119 (2009), 80–90.
23. Grossmann, V., Schmitt, V.H., Zeller, T., Panova-Noeva, M., Schulz, A., Laubert-Reh, D., Juenger, C., Schnabel, R.B., Abt, T.G., Laskowski, R., et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 38 (2015), 1356–1364.
24. Grouwels, G., Cai, Y., Hoebeke, I., Leuckx, G., Heremans, Y., Ziebold, U., Stangé, G., Chintinne, M., Ling, Z., Pipeleers, D., et al. Ectopic expression of E2F1 stimulates beta-cell proliferation and function. Diabetes 59 (2010), 1435–1444.
25. Hajmrle, C., Smith, N., Spigelman, A.F., Dai, X., Senior, L., Bautista, A., Ferdaoussi, M., MacDonald, P.E., Interleukin-1 signaling contributes to acute islet compensation. JCI Insight, 1, 2016, e86055.
26. Herder, C., Brunner, E.J., Rathmann, W., Strassburger, K., Tabák, A.G., Schloot, N.C., Witte, D.R., Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 32 (2009), 421–423.
27. Herder, C., Dalmas, E., Böni-Schnetzler, M., Donath, M.Y., The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab. 26 (2015), 551–563.
28. Herrera, P.L., Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development 127 (2000), 2317–2322.
29. Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.
30. Juge-Aubry, C.E., Somm, E., Giusti, V., Pernin, A., Chicheportiche, R., Verdumo, C., Rohner-Jeanrenaud, F., Burger, D., Dayer, J.M., Meier, C.A., Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52 (2003), 1104–1110.
31. Lacy, P.E., Finke, E.H., Activation of intraislet lymphoid cells causes destruction of islet cells. Am. J. Pathol. 138 (1991), 1183–1190.
32. Lamacchia, C., Palmer, G., Seemayer, C.A., Talabot-Ayer, D., Gabay, C., Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum. 62 (2010), 452–462.
33. Larsen, C.M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J.A., Seifert, B., Mandrup-Poulsen, T., Donath, M.Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007), 1517–1526.
34. Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H.I., Spinas, G.A., Kaiser, N., Halban, P.A., Donath, M.Y., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 (2002), 851–860.
35. Maedler, K., Sergeev, P., Ehses, J.A., Mathe, Z., Bosco, D., Berney, T., Dayer, J.M., Reinecke, M., Halban, P.A., Donath, M.Y., Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc. Natl. Acad. Sci. USA 101 (2004), 8138–8143.
36. Masters, S.L., Latz, E., O'Neill, L.A., The inflammasome in atherosclerosis and type 2 diabetes. Sci. Transl. Med., 3, 2011, 81ps17.
37. Mu, J., Woods, J., Zhou, Y.P., Roy, R.S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A.D., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006), 1695–1704.
38. Nordmann, T.M., Dror, E., Schulze, F., Traub, S., Berishvili, E., Barbieux, C., Böni-Schnetzler, M., Donath, M.Y., The role of inflammation in β-cell dedifferentiation. Sci. Rep., 7, 2017, 6285.
39. Palomo, J., Dietrich, D., Martin, P., Palmer, G., Gabay, C., The interleukin (IL)-1 cytokine family–Balance between agonists and antagonists in inflammatory diseases. Cytokine 76 (2015), 25–37.
40. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S.D., et al., CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377 (2017), 1119–1131.
41. Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3 (2008), 1101–1108.
42. Somm, E., Cettour-Rose, P., Asensio, C., Charollais, A., Klein, M., Theander-Carrillo, C., Juge-Aubry, C.E., Dayer, J.M., Nicklin, M.J., Meda, P., et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 49 (2006), 387–393.
43. Stienstra, R., Joosten, L.A., Koenen, T., van Tits, B., van Diepen, J.A., van den Berg, S.A., Rensen, P.C., Voshol, P.J., Fantuzzi, G., Hijmans, A., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12 (2010), 593–605.
44. Talchai, C., Xuan, S., Lin, H.V., Sussel, L., Accili, D., Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150 (2012), 1223–1234.
45. Thorel, F., Damond, N., Chera, S., Wiederkehr, A., Thorens, B., Meda, P., Wollheim, C.B., Herrera, P.L., Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes 60 (2011), 2872–2882.
46. Traub, S., Meier, D.T., Schulze, F., Dror, E., Nordmann, T.M., Goetz, N., Koch, N., Dalmas, E., Stawiski, M., Makshana, V., et al. Pancreatic α cell-derived glucagon-related peptides are required for β cell adaptation and glucose homeostasis. Cell Rep. 18 (2017), 3192–3203.
47. Vandanmagsar, B., Youm, Y.H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., Ravussin, E., Stephens, J.M., Dixit, V.D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
48. Vetterli, L., Carobbio, S., Pournourmohammadi, S., Martin-Del-Rio, R., Skytt, D.M., Waagepetersen, H.S., Tamarit-Rodriguez, J., Maechler, P., Delineation of glutamate pathways and secretory responses in pancreatic islets with β-cell-specific abrogation of the glutamate dehydrogenase. Mol. Biol. Cell 23 (2012), 3851–3862.
49. Wellen, K.E., Hotamisligil, G.S., Inflammation, stress, and diabetes. J. Clin. Invest. 115 (2005), 1111–1119.
50. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M.T., Brickey, W.J., Ting, J.P., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12 (2011), 408–415.
51. Wu, L., Timmers, C., Maiti, B., Saavedra, H.I., Sang, L., Chong, G.T., Nuckolls, F., Giangrande, P., Wright, F.A., Field, S.J., et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414 (2001), 457–462.
52. Youm, Y.H., Adijiang, A., Vandanmagsar, B., Burk, D., Ravussin, A., Dixit, V.D., Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 152 (2011), 4039–4045.